نتایج جستجو برای: myeloablative

تعداد نتایج: 1963  

2007
Inho Kim Kyung-Hun Lee Yunhee Choi Bhumsuk Keam Nam Hee Koo Sung-Soo Yoon Keun-Young Yoo Seonyang Park Byoung Kook Kim

We compared the outcomes of allogeneic hematopoietic stem cell transplantation using reduced intensity and myeloablative conditioning for the treatment of patients with advanced hematological malignancies. A total of 75 adult patients received transplants from human leukocyte antigen-matched donors, coupled with either reduced intensity (n=40; fludarabine/melphalan, 28; fludarabine/cyclophospha...

Journal: :Haematologica 2017
Shannon R McCurdy Yvette L Kasamon Christopher G Kanakry Javier Bolaños-Meade Hua-Ling Tsai Margaret M Showel Jennifer A Kanakry Heather J Symons Ivana Gojo B Douglas Smith Maria P Bettinotti William H Matsui Amy E Dezern Carol Ann Huff Ivan Borrello Keith W Pratz Douglas E Gladstone Lode J Swinnen Robert A Brodsky Mark J Levis Richard F Ambinder Ephraim J Fuchs Gary L Rosner Richard J Jones Leo Luznik

Composite endpoints that not only encompass mortality and relapse, but other critical post-transplant events such as graft-versus-host disease, are being increasingly utilized to quantify survival without significant morbidity after allogeneic blood or marrow transplantation. High-dose, post-transplantation cyclophosphamide reduces severe graft-versus-host disease with allogeneic marrow transpl...

2003
Christine M. Segeren Pieter Sonneveld Bronno van der Holt Edo Vellenga Alexandra J. Croockewit Gregor E. G. Verhoef Jan J. Cornelissen Martijn R. Schaafsma Marinus H. J. van Oers Pierre W. Wijermans Wim E. Fibbe Shulamit Wittebol Harry C. Schouten Marinus van Marwijk Kooy Douwe H. Biesma Joke W. Baars Rosalyn Slater Monique M. C. Steijaert Ivon Buijt Henk M. Lokhorst

We compared the efficacy of intensified chemotherapy followed by myeloablative therapy and autologous stem cell rescue with intensified chemotherapy alone in patients newly diagnosed with multiple myeloma. There were 261 eligible patients younger than 66 years with stage II/III multiple myeloma who were randomized after remission induction therapy with vincristine, adriamycin, dexamethasone (VA...

Journal: :Blood 2001
C D Bolan S F Leitman L M Griffith R A Wesley J L Procter D F Stroncek A J Barrett R W Childs

Delayed donor red cell engraftment and pure red cell aplasia (PRCA) are well-recognized complications of major ABO-incompatible hematopoietic stem cell transplantation (SCT) performed by means of myeloablative conditioning. To evaluate these events following reduced-intensity nonmyeloablative SCT (NST), consecutive series of patients with major ABO incompatibility undergoing either NST (fludara...

Journal: :Blood 2012
Bruno Lioure Marie C Béné Arnaud Pigneux Anne Huynh Patrice Chevallier Nathalie Fegueux Didier Blaise Brigitte Witz Martine Delain Jérôme Cornillon Isabelle Luquet Odile Blanchet Pascale Cornillet-Lefebvre Martin Carré Mathilde Hunault Fabrice Larosa Thierry Lamy Edouard Randriamalala Mario Ojeda-Uribe Christian Berthou Luc Fornecker Jean-Luc Harousseau Didier Bouscary Norbert Ifrah Jean-Yves Cahn

The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger p...

Journal: :Cytotherapy 2021

Background aimsTo reduce the risk of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT), T-cell depletion (TCD) grafts can be performed by addition alemtuzumab (ALT) “to bag” (in vitro) before transplantation. In this prospective study, authors analyzed effect in vitro incubation with 20 mg ALT on composition prior to graft infusion. Furthermore, assessed whet...

2017

Non-Hodgkin Lymphoma (NHL) B-Cell aggressive subtype (except mantle cell) Myeloablative autologous, myeloablative allogeneic or reduced-intensity conditioning (RIC) allogeneic HSCT with curative intent may be considered medically necessary:  As salvage for patients not in complete remission (CR) after first line chemotherapy induction;  To achieve or consolidate a CR in chemotherapy sensitive...

Journal: :Hematology. American Society of Hematology. Education Program 2002
David G Maloney Brenda M Sandmaier Stephen Mackinnon Judith A Shizuru

The concept of utilizing enhanced immunosuppression rather than myeloablative cytotoxic conditioning has allowed the engraftment of allogeneic stem cells from related and unrelated donors with lower early transplant-related mortality (TRM) and morbidity. This approach shifts tumor eradication to the graft-vs-host immune response directed against minor histocompatibility antigens expressed on tu...

Journal: :Haematologica 2016
Bipin N Savani Myriam Labopin Nicolaus Kröger Jürgen Finke Gerhard Ehninger Dietger Niederwieser Rainer Schwerdtfeger Donald Bunjes Bertram Glass Gerard Socié Per Ljungman Charles Craddock Frédéric Baron Fabio Ciceri Norbert Claude Gorin Jordi Esteve Christoph Schmid Sebastian Giebel Mohamad Mohty Arnon Nagler

The outcome of patients undergoing HLA-matched unrelated donor allogeneic hematopoietic cell transplantation following reduced-intensity conditioning or myeloablative regimens is reported to be equivalent; however, it is not known if the intensity of the conditioning impacts outcomes after mismatched unrelated donor transplantation for acute myeloid leukemia. Eight hundred and eighty three pati...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید